India’s Dr. Reddy’s, Natco Strike Deal To Target Abraxane And Several Other Oncology Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Highly profitable generic drugs - mainly in the oncology segment - are the latest targets for Indian pharmaceutical companies as margins rapidly shrink on commoditized off-patent drugs in the U.S. and several other markets. With that objective, India's Dr. Reddy's Labs and Natco, a company specializing in oncology drugs have signed a deal for the development, manufacture and supply of a basket of value added generic oncology drugs
You may also be interested in...
United And Divided: Natco's Patent Challenge On Revlimid Leads Dr. Reddy's To Up Its Pitch
MUMBAI - Natco Pharma's patent challenge earlier this month over Celgene's blockbuster multiple myeloma drug Revlimid (lenalidomide) has led India's Dr. Reddy's Labs to fast-track its own development of the product, which was brought under a restricted distribution plan by U.S. FDA due to its risky profile
United And Divided: Natco's Patent Challenge On Revlimid Leads Dr. Reddy's To Up Its Pitch
MUMBAI - Natco Pharma's patent challenge earlier this month over Celgene's blockbuster multiple myeloma drug Revlimid (lenalidomide) has led India's Dr. Reddy's Labs to fast-track its own development of the product, which was brought under a restricted distribution plan by U.S. FDA due to its risky profile
Natco Gets Defensive As Indian Regulator Threatens Criminal Action For Marketing Substandard Product
MUMBAI - Albumin-bound paclitaxel drug Abraxane - used in the treatment of breast cancer - has been troubling its innovator, Abraxis Bioscience, and its only Indian generic maker, Natco Pharma, alike